鴉片類藥物使用障礙全球市場規模、佔有率、趨勢和成長分析報告（2026-2034）

鴉片類藥物使用障礙市場預計將從 2025 年的 60.7 億美元成長到 2034 年的 170.6 億美元，2026 年至 2034 年的複合年成長率為 12.17%。

隨著醫療保健系統將重點放在有效的治療策略和危害緩解措施上，鴉片類藥物使用障礙市場正在經歷重大變革時期。鴉片類藥物成癮和過量用藥案例的增加，推動了對先進治療性介入，包括Buprenornhine、美沙酮和新興的非鴉片類藥物療法。結合藥物治療支持（MAT）、行為療法和數位化藥物依從性監測的綜合護理模式，對於長期康復至關重要。監管措施和公共衛生宣傳活動正在進一步加速患者獲得創新治療方法。

技術和臨床的進步正在提升治療的有效性和可近性。數位健康平台提供遠端監測、風險預測預警和用藥依從性追蹤等功能，從而實現個人化治療策略。新型藥物製劑，例如緩釋製劑和舌下給藥系統，在提高患者依從性的同時，也降低了藥物濫用的風險。對非依賴性鎮痛藥、疫苗干預和神經調控療法的研究正在開闢新的治療途徑。醫療服務提供者正積極利用遠端醫療和行動醫療技術，擴大服務不足人口的就醫範圍，並提高介入措施的成功率。

未來的發展將由綜合公共衛生策略、政策支援和藥物創新共同塑造。北美地區由於其高發病率和成熟的治療體系，仍然是最大的市場；同時，新興經濟體獲得實證治療的機會也逐漸擴大。醫療服務提供者、數位健康創新者和製藥公司之間的策略合作正在建立一個全面支持診斷、治療和復健的生態系統。隨著公眾意識的提高、技術的進步和治療方案的增多，鴉片類藥物使用障礙市場有望提供更有效、以患者為中心的解決方案，以應對醫療和社會方面的挑戰。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球鴉片類藥物使用障礙市場：依藥物分類

• 市場分析、洞察與預測
• 納曲酮
• Buprenornhine
• 梅薩頓
• 其他

第5章 全球鴉片類藥物使用障礙市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 注射給藥
• 其他

第6章：全球鴉片類藥物使用障礙市場：依分銷管道分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第7章 全球鴉片類藥物使用障礙市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Indivior PLC
  • Teva Pharmaceutical Industries Ltd
  • Pfizer Inc
  • Collegium Pharmaceutical（BioDelivery Sciences International Inc.）
  • Alkermes Inc
  • Orexo US Inc.（A Part Of Orexo AB）
  • Titan Pharmaceuticals Inc
  • Omeros Corporation
  • Camurus AB
  • Hikma Pharmaceuticals PLC

The Opioids Use Disorder Market size is expected to reach USD 17.06 Billion in 2034 from USD 6.07 Billion (2025) growing at a CAGR of 12.17% during 2026-2034.

The opioids use disorder market is undergoing significant evolution as healthcare systems prioritize effective treatment strategies and harm reduction measures. Rising prevalence of opioid dependence and overdose incidents has intensified demand for advanced therapeutic interventions, including buprenorphine, methadone, and emerging non-opioid pharmacotherapies. Integrated care models combining medication-assisted treatment (MAT), behavioral therapy, and digital adherence monitoring are becoming essential for long-term recovery outcomes. Regulatory initiatives and public health campaigns are further supporting patient access to innovative therapies.

Technological and clinical advancements are expanding treatment efficacy and accessibility. Digital health platforms provide remote monitoring, predictive risk alerts, and adherence tracking, enabling personalized treatment strategies. Novel drug formulations, including extended-release and sublingual delivery systems, are improving patient compliance while reducing misuse potential. Research into non-addictive analgesics, vaccine-based interventions, and neuromodulation therapies is creating new therapeutic avenues. Healthcare providers are increasingly leveraging telemedicine and mobile health technologies to reach underserved populations and improve intervention success rates.

The future trajectory is defined by integrated public health strategies, policy support, and pharmaceutical innovation. North America remains the largest market due to high prevalence and mature treatment infrastructure, while emerging economies are gradually scaling access to evidence-based therapies. Strategic partnerships between healthcare providers, digital health innovators, and pharmaceutical companies are fostering a comprehensive ecosystem for diagnosis, treatment, and recovery support. As awareness, technology, and therapeutic options expand, the opioids use disorder market is poised to provide more effective, patient-centric solutions that address both medical and societal challenges.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug

• Naltrexone
• Buprenorphine
• Methadone
• Others

By Route of Administration

• Oral Administration
• Injectable Administration
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Indivior PLC, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Collegium Pharmaceutical BioDelivery Sciences International Inc, Alkermes Inc, Orexo US Inc a part of Orexo AB, Titan Pharmaceuticals Inc, Omeros Corporation, Camurus AB, Hikma Pharmaceuticals PLC
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL OPIOIDS USE DISORDER MARKET: BY DRUG 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug
• 4.2. Naltrexone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Buprenorphine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Methadone Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OPIOIDS USE DISORDER MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Injectable Administration Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OPIOIDS USE DISORDER MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OPIOIDS USE DISORDER MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OPIOIDS USE DISORDER INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Indivior PLC
  • 9.2.2 Teva Pharmaceutical Industries Ltd
  • 9.2.3 Pfizer Inc
  • 9.2.4 Collegium Pharmaceutical (BioDelivery Sciences International Inc.)
  • 9.2.5 Alkermes Inc
  • 9.2.6 Orexo US Inc. (A Part Of Orexo AB)
  • 9.2.7 Titan Pharmaceuticals Inc
  • 9.2.8 Omeros Corporation
  • 9.2.9 Camurus AB
  • 9.2.10 Hikma Pharmaceuticals PLC